IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

The US FDA has granted fast track designation to ID161, a selective, potent poly ADP-ribose inhibitor glycohydrolase for patients with advanced or metastatic HR+, HER2- breast cancer with germline or somatic BRCA 1/ 2 mutations who experienced progression after treatment with hormonal therapy.

Access the full article to read more here.